Cipla Launches Authorized Generic of Aloxi

Cipla has launched an authorized generic version of Aloxi in the United States of America under applicable agreements with Helsinn Healthcare SA, in response to the at-risk launch by Teva. Helsinn Healthcare currently manufactures and markets Aloxi in the United States of America through its licensee Eisai Inc. and its affiliate Helsinn Therapeutics Inc.

Aloxi containing palonosetron hydrochloride injections (eq. 0.25 mg base/5 ml) is indicated for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy and for prevention of acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. According to IMS Health, Aloxi brand had US sales of approximately USD 460 million for the 12-month period ending November 2017. Cipla’s authorized generic of Aloxi is available for shipping immediately.